Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combination raltitrexed (Tomudex (R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma
Autore:
Fizazi, K; Caliandro, R; Soulie, P; Fandi, A; Daniel, C; Bedin, A; Doubre, H; Viala, J; Rodier, JM; Trandafir, L; Le Chevalier, T; Cvitkovic, E; Armand, JP; Ruffie, P;
Indirizzi:
Inst Gustave Roussy, Dept Med, F-94800 Villejuif, France Inst Gustave Roussy Villejuif France F-94800 , F-94800 Villejuif, France
Titolo Testata:
EUROPEAN JOURNAL OF CANCER
fascicolo: 12, volume: 36, anno: 2000,
pagine: 1514 - 1521
SICI:
0959-8049(200008)36:12<1514:CR((AS>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
MALIGNANT PLEURAL MESOTHELIOMA; PHASE-II TRIAL; LEUKEMIA GROUP-B; DNA MISMATCH REPAIR; INTERFERON ALFA-2A; ALPHA-INTERFERON; MITOMYCIN-C; BETA-SER; CISPLATIN; CANCER;
Keywords:
mesothelioma; chemotherapy; immunotherapy; raltitrexed; oxaliplatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
61
Recensione:
Indirizzi per estratti:
Indirizzo: Fizazi, K Inst Gustave Roussy, Dept Med, 39 Rue Camille Desmoulins, F-94800 Villejuif, France Inst Gustave Roussy 39 Rue Camille Desmoulins Villejuif France F-94800
Citazione:
K. Fizazi et al., "Combination raltitrexed (Tomudex (R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma", EUR J CANC, 36(12), 2000, pp. 1514-1521

Abstract

The aim of this study was to review the experience of the Institut GustaveRoussy in 163 patients with malignant mesothelioma over a 9-year period. Data from seven consecutive prospective trials, four of chemo-immunotherapy and three of chemotherapy were reviewed. The rationale, methods and resultsof these trials are summarised and discussed. 98 patients were included infour phase II trials of chemo-immunotherapy whose common denominator was acombination of cisplatin and alpha-interferon. The response rate ranged from 15% to 40%. High-dose weekly cisplatin combined with alpha-interferon yielded the highest response rate but the toxicity of this regimen was considered unacceptable. Neither higher doses of alpha-interferon or the additionof mitomycin C or interleukin-2 to the regimen were able to enhance the activity of this combination. 18 patients were included in a paclitaxel-cisplatin phase II trial. The response rate was only 6% (95% confidence interval(CI): 0-24) and toxicity was also significant. This regimen was. therefore, considered ineffective. Of 17 patients with mesothelioma included in a phase I trial that combined raltitrexed and oxaliplatin, 6 (35%) obtained a partial response. Responses were seen even in cisplatin-refractory mesothelioma. Preliminary results of a subsequent ongoing phase TI trial using raltitrexed (3 mg/m(2)) and oxaliplatin (130 mg/m(2)) have confirmed this promising activity with a 30% (9/30) response rate (95% CI: 15-49). The toleranceof this outpatient regimen is acceptable (no significant haematological toxicity and no alopecia) and compares favourably with that of our previous regimens. The final results concerning response and survival are required toconfirm the efficacy of this combination. The preliminary results of two studies suggest promising activity with the combination of raltitrexed-oxaliplatin in malignant mesothelioma. The efficacy/toxicity ratio of this combination compares favourably with that of our previous chemotherapy and chemo-immunotherapy regimens. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 13:10:26